New Blood Test Catches Deadly Pancreatic Cancer Early

A simple blood test may soon catch pancreatic cancer before it becomes a death sentence.

Researchers at the University of Pennsylvania and Mayo Clinic have developed a screening test that identifies pancreatic ductal adenocarcinoma in its early stages with 87.5% accuracy. The test combines four protein markers found in blood samples, two of which are entirely new discoveries.

Pancreatic cancer is notoriously lethal because doctors rarely find it before it spreads. Only 1 in 10 patients survives more than five years after diagnosis. The cancer hides quietly in the body, showing few symptoms until it reaches advanced stages when treatment rarely works.

The research team started with two known cancer markers, CA19-9 and THBS2, but neither worked well alone for screening. CA19-9 shows up in people with harmless conditions like pancreatitis, while some people don't produce it at all due to their genetics.

Then they discovered two new markers, ANPEP and PIGR, in banked blood samples from early-stage cancer patients. When all four markers worked together, the test successfully identified cancer 91.9% of the time across all stages, with only 5% false positives.

The test excelled at a crucial challenge: telling the difference between cancer patients and people with non-cancerous pancreatic conditions like pancreatitis. Previous screening attempts often failed this critical distinction.

Why This Inspires

This breakthrough represents hope for thousands of families who lose loved ones to pancreatic cancer each year. Early detection transforms this disease from a near-certain death sentence into a treatable condition.

Lead investigator Kenneth Zaret sees the test's potential clearly. "By adding ANPEP and PIGR to the existing markers, we've significantly improved our ability to detect this cancer when it's most treatable," he explained.

The team now wants to test their discovery in larger populations, particularly people showing no symptoms yet. They're especially interested in screening high-risk groups: people with family histories of pancreatic cancer, certain genetic markers, or personal histories of pancreatic cysts or pancreatitis.

If larger studies confirm these results, doctors could finally screen vulnerable patients before cancer takes hold. That simple blood draw could buy precious time when treatment actually works.